Clinical Trial · NCT07114939

PARP-1 Targeting With the Novel Radiotracer [18F]FTT in Pancreatic Neuroendocrine Tumors

Overview

A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, [18F]FluorThanatrace ([18F]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of [18F]FTT (±20%) for a total of 60 minutes. A static scan at 90 minutes post injection will subsequently be obtained. [18F]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.

Sponsor

Abramson Cancer Center of the University of Pennsylvania

Phase

Phase 1

Contacts

Erin K Schubert, MS

erinschu@pennmedicine.upenn.edu

215-573-6569

ClinicalTrials.gov

NCT07114939

Drug / Compound

[18F]FluorThanatrace

Isotope(s):

Target(s):

PARP